Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

New research uncovers mechanisms behind heart damage from CTLA-4 blockade

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells.

August 7, 2024

European supergroup launches to tackle diversity in clinical trials – Pharmaceutical Technology

The overall aim of the group will be to raise awareness and improve understanding of diversity, as well as the characteristics of underrepresented and underserved

January 16, 2025

Roundup: Cyber incidents, vulnerabilities hit the medtech sector in 2023

Cybersecurity has been a top issue over the past several years for the healthcare industry overall, as cyber attackers have targeted hospitals and sensitive patient

December 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.